Evidence of Long-term Survival Benefit in ALS with CNM-Au8 30 mg Treatment Across Three Study Populations

Marjan Sepassi, PharmD; James D. Berry, MD, MPH; Nicholas Maragakis, MD; Sabrina Paganoni, MD, PhD; Melanie Quintana, PhD; Eric A. Macklin, PhD; Benjamin R. Saville, PhD; Jinsy Andrews, MD; Jeremy Shefner, MD, PhD; Michelle A. Detry, PhD; Elijah Stommel MD, Parvathi Menon PhD, FRACP, William Huynh PhD, FRACP, Colin Mahoney, PhD, MB, MRCPI; Meghan Hall; Mariah Connolly; Gale Kittle; Marianne Chase; Alex Sherman; Hong Yu; Lindsay Pothier; Kristin Drake, MBA; Lori Chibnik, PhD, MPH; Marie-Abele Bind, PhD; Matteo Vestrucci, PhD; Austin Rynders, RN; Jacob Evan; Jeremy Evan, PA-C; Karen S. Ho, PhD, MSc; Alan Hartford, PhD; Ben Greenberg, MD; Steve Vucic Dsc, PhD, FRACP, FAHMS; Matthew C. Kiernan, DSc, PhD, MBBS, FRACP, FAHMS; Merit E. Cudkowicz, MD; and Michael T. Hotchkin for the HEALEY ALS Platform Trial Study Group and RESCUE-ALS Investigators

RESULTS: Long-term follow-up from RESCUE-ALS and the HEALEY ALS Platform Trial provide evidence of improved survival with CNM-Au8 30mg, reinforced by real-world data from expanded access programs

HEALEY ALS Platform Trial

Optimal Variable Ratio Matching
Prespecified Matching Methodology

Original Randomized CNM-Au8 30 mg vs. Propensity Matched Controls
HEALEY ALS Platform Trial | Optimal Variable Matching
Pooled Matched Controls (PRO-ACT, ALS NHC, ANSWER-ALS)



At Risk							
CNM-Au8 30 mg:	59	58	53	41	31	23	12
Matched Controls:	177	153	112	65	43	28	19

Nearest Neighbor (Greedy) Matching
Sensitivity Matching Methodology

Original Randomized CNM-Au8 30 mg vs. Propensity Matched Controls
HEALEY ALS Platform Trial | Greedy Nearest Neighbor Match
Pooled Matched Controls (PRO-ACT, ALS NHC, ANSWER-ALS)



At Risk							
CNM-Au8 30 mg:	59	58	53	41	31	23	12
Matched Controls:	172	144	110	52	31	21	10

HEALEY ALS Platform Trial
RESCUEALS

Optimal Variable Ratio Matching
Prespecified Matching Methodology

Original Randomized CNM-Au8 30 mg vs. Propensity Matched Controls
Pooled HEALEY ALS Platform Trial & RESCUE-ALS | Optimal Variable Matching
Pooled Matched Controls (PRO-ACT, ALS NHC, ANSWER-ALS)



At Risk							
CNM-Au8 30 mg:	82	81	73	59	45	35	23
Matched Controls:	246	211	147	78	52	31	23

Nearest Neighbor (Greedy) Matching
Sensitivity Matching Methodology

Original Randomized CNM-Au8 30 mg vs. Propensity Matched Controls
HEALEY ALS Platform Trial & RESCUE-ALS | Greedy Nearest Neighbor Match
Pooled Matched Controls (PRO-ACT, ALS NHC, ANSWER-ALS)



At Risk							
CNM-Au8 30 mg:	82	81	73	59	45	35	23
Matched Controls:	241	197	144	83	59	36	21

ALS EXPANDED ACCESS PROTOCOLS (EAP)

Optimal Variable Ratio Matching
Prespecified Matching Methodology

CNM-Au8 30 mg EAP Participants vs. Propensity Matched Controls
CNM-Au8 30 mg (EAP01 & EAP02) All Evaluable with Baseline Covariates vs.
Pooled Matched Controls (PRO-ACT, ALS NHC, ANSWER-ALS)
Optimal Variable Ratio Matching



At Risk							
CNM-Au8 30 mg:	258	206	112	61	58	53	33
Matched Controls:	774	656	485	280	186	126	76

Nearest Neighbor (Greedy) Matching
Sensitivity Matching Methodology

CNM-Au8 30 mg EAP Participants vs. Propensity Matched Controls
CNM-Au8 30 mg (EAP01 & EAP02) All Evaluable with Baseline Covariates vs.
Pooled Matched Controls (PRO-ACT, ALS NHC, ANSWER-ALS)
Nearest Neighbor Matching | Matched Population Only



At Risk							
CNM-Au8 30 mg:	240	190	106	58	56	51	31
Matched Controls:	557	463	356	219	148	108	73

Methods

Propensity Matching: Optimal Variable Ratio (Prespecified) **and Nearest Neighbor** (Sensitivity)**; Pooled Control Set:** PRO-ACT, ALS Natural History Consortium (ALS NHC), ANSWER-ALS (i.e., widest possible pool for matching); **Matching Allocation**: 1:3 (active:control) match; **Logit Caliper Width:** 0.2; **Matching Covariates:** (i) BMI, (ii) Sex, (iii) Bulbar Onset, (iv) Months from Symptom Onset, (v) Onset Age, (vi) Diagnostic Delay (Months), (vii) ALSFRS-R Pre-Treatment Slope, (viii) ALSFRS-R Total Score, (ix) Vital Capacity (% predicted), (x) VC (% predicted) Pre-Treatment Slope, (xi) TRICALS Risk Score; **Survival Cox Proportional Hazard Ratio Model Baseline Covariates:** (i) Bulbar Onset, (ii) Onset Age, (iii) Sex, (iv) BMI, (v) Pre-treatment ALSFRS-R slope, (vi) ALSFRS-R Total Score, (vii) Diagnostic Delay (in months), (viii) Vital Capacity (% predicted), (ix) Pre-Treatment Vital Capacity Slope, and (x) TRICALS Risk Score. **Notes:** Includes all evaluable participants with complete baseline covariates for matching. Participants are right censored at last observation (death or any reported clinical or laboratory value). When less than ~10% follow-up information is available in both groups (active and matched controls), Kaplan-Meier figures are truncated thereafter (Hazard Ratios include all follow-up data in all participants).
Survival (time to all-cause mortality) does not include permanent assisted ventilation, which was not tracked consistently in the control datasets.

Acknowledgements: We are indebted to the participants and investigators of the HEALEY ALS Platform Trial, the RESCUE-ALS trial, and the U.S. Expanded Access Protocols (EAPs).

CLene NANOMEDICINE